%0 Journal Article
%A Brinkmann, Berit J
%A Floerchinger, Alessia
%A Schniederjohann, Christina
%A Roider, Tobias
%A Coelho, Mariana
%A Mack, Norman
%A Bruch, Peter-Martin
%A Liebers, Nora
%A Dötsch, Sarah
%A Busch, Dirk H
%A Schmitt, Michael
%A Neumann, Frank
%A Roessner, Philipp M
%A Seiffert, Martina
%A Dietrich, Sascha
%T CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
%J Blood
%V 144
%N 7
%@ 0006-4971
%C Washington, DC
%I American Society of Hematology
%M DKFZ-2024-01152
%P 784-789
%D 2024
%Z 2024 Aug 15;144(7):784-789
%X Anti-CD19 chimeric antigen receptor T-cells (CD19-CAR) represent an effective treatment for relapsed/refractory B-cell malignancies but incomplete responses often result in early disease progression. We here assessed potential benefits of co-administering CD20-targeting bispecific antibodies (CD20-BsAb) with CD19-CAR, aiming to enhance immunotherapeutic efficacy. Addition of CD20-BsAb to co-cultures of CD19-CAR and primary samples of B-cell malignancies, comprising malignant B- and endogenous T-cells, significantly improved killing of malignant cells alongside enhanced expansion of both endogenous T-cells and CD19-CAR. CD20-BsAb induced an increase in proliferation and activation of endogenous T-cells and CD19-CAR. In an immunocompetent mouse model of CLL, relapse after initial treatment response frequently occurred after CD19-CAR monotherapy. Combination with injections of CD20-BsAb significantly enhanced treatment response and resulted in improved eradication of malignant cells. Higher efficacy was accompanied by improved T-cell expansion upon CD20-BsAb administration and resulted in longer survival, with 80
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38805637
%R 10.1182/blood.2023022682
%U https://inrepo02.dkfz.de/record/290535